Entera Bio Ltd
ENTX
View Detailed Chart
1.040USD
-0.130-11.11%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
47.49MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-11.11%
5 Days
-24.09%
1 Month
-33.76%
6 Months
-47.47%
Year to Date
-46.39%
1 Year
-58.73%
View Detailed Chart
TradingKey Stock Score of Entera Bio Ltd
Currency: USD Updated: 2026-02-06Key Insights
Entera Bio Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 142 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Entera Bio Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Entera Bio Ltd Highlights
StrengthsRisks
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 35.07% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 181.00K.
Fairly Valued
The company’s latest PE is -4.26, at a medium 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 88.40K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.48.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
10.000
Target Price
+754.70%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Entera Bio Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Entera Bio Ltd Info
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
Ticker SymbolENTX
CompanyEntera Bio Ltd
CEOToledano (Miranda Jayne)
Websitehttps://enterabio.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68959.740
-1010.390 (-1.44%)
282.580
+22.390 (+8.61%)
2033.290
-18.440 (-0.90%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
